Hamilton, Canada
Hamilton, Canada

Hamilton Health science is a medical group of six unique hospitals and a cancer centre located in Hamilton, Ontario, Canada. Wikipedia.


Time filter

Source Type

Trigatti B.L.,Hamilton Health Sciences
Current Opinion in Lipidology | Year: 2017

PURPOSE OF REVIEW: To outline the roles of SR-B1 and PDZK1 in hepatic selective HDL cholesterol uptake and reverse cholesterol transport and the consequences for atherosclerosis development. RECENT FINDINGS: Much of our understanding of the physiological roles of SR-B1 and PDZK1 in HDL metabolism and atherosclerosis comes from studies of genetically manipulated mice. These show SR-B1 and PDZK1 play key roles in HDL metabolism and protection against atherosclerosis. The recent identification of rare loss of function mutations in the human SCARB1 gene verifies that it plays similar roles in HDL metabolism in humans. Other rare mutations in both the human SCARB1 and PDZK1 genes remain to be characterized but may have potentially devastating consequences to SR-B1 function. SUMMARY: Identification of carriers of rare mutations in human SCARB1 and PDZK1 that impair the function of their gene products and characterization of the effects of these mutations on HDL cholesterol levels and atherosclerosis will add to our understanding of the importance of HDL function and cholesterol flux, as opposed to HDL-cholesterol levels, per se, for protection against cardiovascular disease. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.


News Article | May 23, 2017
Site: www.eurekalert.org

Hamilton, ON (May 23, 2017) - Probiotics may relieve symptoms of depression, as well as help gastrointestinal upset, research from McMaster University has found. In a study published in the medical journal Gastroenterology (May 2), researchers of the Farncombe Family Digestive Health Research Institute found that twice as many adults with irritable bowel syndrome (IBS) reported improvements from co-existing depression when they took a specific probiotic than adults with IBS who took a placebo. The study provides further evidence of the microbiota environment in the intestines being in direct communication with the brain said senior author Dr. Premysl Bercik, an associate professor of medicine at McMaster and a gastroenterologist for Hamilton Health Sciences. "This study shows that consumption of a specific probiotic can improve both gut symptoms and psychological issues in IBS. This opens new avenues not only for the treatment of patients with functional bowel disorders but also for patients with primary psychiatric diseases," he said. IBS is the most common gastrointestinal disorder in the world, and is highly prevalent in Canada. It affects the large intestine and patients suffer from abdominal pain and altered bowel habits like diarrhea and constipation. They are also frequently affected by chronic anxiety or depression. The pilot study involved 44 adults with IBS and mild to moderate anxiety or depression. They were followed for 10 weeks, as half took a daily dose of the probiotic Bifidobacterium longum NCC3001, while the others had a placebo. At six weeks, 14 of 22, or 64%, of the patients taking the probiotic had decreased depression scores, compared to seven of 22 (or 32%) of patients given placebo. Functional Magnetic Resonance Imaging (fMRI) showed that the improvement in depression scores was associated with changes in multiple brain areas involved in mood control. "This is the result of a decade long journey - from identifying the probiotic, testing it in preclinical models and investigating the pathways through which the signals from the gut reach the brain," said Bercik. "The results of this pilot study are very promising but they have to be confirmed in a future, larger scale trial," said Dr. Maria Pinto Sanchez, the first author and a McMaster clinical research fellow. The study was performed in collaboration with scientists from Nestlé. For more information: Veronica McGuire Media Relations Faculty of Health Sciences McMaster University vmcguir@mcmaster.ca 905-525-9140, ext. 22169


News Article | May 25, 2017
Site: www.sciencedaily.com

Probiotics may relieve symptoms of depression, as well as help gastrointestinal upset, research from McMaster University has found. In a study published in the medical journal Gastroenterology, researchers of the Farncombe Family Digestive Health Research Institute found that twice as many adults with irritable bowel syndrome (IBS) reported improvements from co-existing depression when they took a specific probiotic than adults with IBS who took a placebo. The study provides further evidence of the microbiota environment in the intestines being in direct communication with the brain said senior author Dr. Premysl Bercik, an associate professor of medicine at McMaster and a gastroenterologist for Hamilton Health Sciences. "This study shows that consumption of a specific probiotic can improve both gut symptoms and psychological issues in IBS. This opens new avenues not only for the treatment of patients with functional bowel disorders but also for patients with primary psychiatric diseases," he said. IBS is the most common gastrointestinal disorder in the world, and is highly prevalent in Canada. It affects the large intestine and patients suffer from abdominal pain and altered bowel habits like diarrhea and constipation. They are also frequently affected by chronic anxiety or depression. The pilot study involved 44 adults with IBS and mild to moderate anxiety or depression. They were followed for 10 weeks, as half took a daily dose of the probiotic Bifidobacterium longum NCC3001, while the others had a placebo. At six weeks, 14 of 22, or 64%, of the patients taking the probiotic had decreased depression scores, compared to seven of 22 (or 32%) of patients given placebo. Functional Magnetic Resonance Imaging (fMRI) showed that the improvement in depression scores was associated with changes in multiple brain areas involved in mood control. "This is the result of a decade long journey -- from identifying the probiotic, testing it in preclinical models and investigating the pathways through which the signals from the gut reach the brain," said Bercik. "The results of this pilot study are very promising but they have to be confirmed in a future, larger scale trial," said Dr. Maria Pinto Sanchez, the first author and a McMaster clinical research fellow.


The government's plan is to close 5 entire community hospitals in Niagara in the communities of Welland, Port Colborne, Fort Erie, Niagara-on-the-Lake and Niagara Falls. They claim that they will build one hospital to replace all five, on the southern outskirts of Niagara Falls. The Welland hospital services the medical needs of 100,000 Welland and area residents. Our campaigns have pushed back plans, but the currently-proposed ambulatory care centre to replace the hospital will not provide in-patient health care services, emergency care, nor complex and acute care. It will not be a hospital. In addition, plans to totally close the hospitals and a number of urgent care centres in South Niagara are still in the works. The Niagara-on-the-Lake hospital has already been closed as a hospital. Plans for any new hospital are not concrete and will take a decade or more, if they ever materialize. In addition, there are plans to close 2 entire hospitals in Hamilton and dramatically restructure all the hospitals around the Hamilton-to-Niagara region. The Grimsby hospital (West Lincoln Memorial) was swallowed up by Hamilton Health Sciences after the provincial government axed the new hospital in that community that it had previously approved. These changes along with the cuts in Niagara will dramatically impact access to care for millions of people in the Hamilton Niagara region. The hostipals closures must be stopped and restructuring plans deserve full scrutiny and public debate. May 31, 2017: Media Event: At the Provincial Legislature, Queen's Park, Ontario (North Doorss)


The government's plan is to close 5 entire community hospitals in Niagara in the communities of Welland, Port Colborne, Fort Erie, Niagara-on-the-Lake and Niagara Falls. They claim that they will build one hospital to replace all five, on the southern outskirts of Niagara Falls. The Welland hospital services the medical needs of 100,000 Welland and area residents. Our campaigns have pushed back plans, but the currently-proposed ambulatory care centre to replace the hospital will not provide in-patient health care services, emergency care, nor complex and acute care. It will not be a hospital. In addition, plans to totally close the hospitals and a number of urgent care centres in South Niagara are still in the works. The Niagara-on-the-Lake hospital has already been closed as a hospital. Plans for any new hospital are not concrete and will take a decade or more, if they ever materialize. In addition, there are plans to close 2 entire hospitals in Hamilton and dramatically restructure all the hospitals around the Hamilton-to-Niagara region. The Grimsby hospital (West Lincoln Memorial) was swallowed up by Hamilton Health Sciences after the provincial government axed the new hospital in that community that it had previously approved. These changes along with the cuts in Niagara will dramatically impact access to care for millions of people in the Hamilton Niagara region. The hospital closures must be stopped and restructuring plans deserve full scrutiny and public debate. May 31, 2017: Media Event: At the Provincial Legislature, Queen's Park, Ontario (North Doorss)


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.2-2 | Award Amount: 7.85M | Year: 2011

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain. Based on harmonised and standardised European population cohorts we have built significant research collaboration, expertise and infrastructure in the EU. We will apply highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers. Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems biomarkers will be tested and validated in a stepwise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated. We will establish a BiomarCaRE panel which leads to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path towards personalised medicine.


Vege S.S.,Mayo Medical School | Ziring B.,Thomas Jefferson University | Jain R.,Texas Digestive Disease Consultants | Moayyedi P.,Hamilton Health Sciences
Gastroenterology | Year: 2015

This article has an accompanying continuing medical education activity on page e12. Learning Objective: At the conclusion of this exercise, the learner will understand the approach to counseling patients regarding the optimal method and frequency of radiologic imaging, indications for invasive tests like endoscopic ultrasonography (EUS) and surgery, select patients for follow-up after surgery, decide the duration of such follow-up, and decide when to stop surveillance for those with and without surgery. © 2015 by the AGA Institute.


Connolly B.S.,Hamilton Health Sciences | Lang A.E.,Toronto Western Hospital | Lang A.E.,University of Toronto
JAMA - Journal of the American Medical Association | Year: 2014

IMPORTANCE: Parkinson disease is the second most common neurodegenerative disease worldwide. Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life. OBJECTIVE: To provide an evidence-based review of the initial pharmacological management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eyemovement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea. EVIDENCE REVIEW: References were identified using searches of PubMed between January 1985 and February 2014 for English-language human studies and the full database of the Cochrane Library. The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurology and the highest-quality data for each topic. RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications. Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists. Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists. Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality positive studies. CONCLUSIONS AND RELEVANCE: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease. Dopamine agonists and drugs that block dopamine metabolism are effective for motor fluctuations and clozapine is effective for hallucinations. Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression. Evidence supporting other therapies for motor and nonmotor features is less well established. Copyright 2014 American Medical Association. All rights reserved.


Warkentin T.E.,McMaster University | Warkentin T.E.,Hamilton Health Sciences
Seminars in Thrombosis and Hemostasis | Year: 2015

Many critically ill patients receive heparin, either before intensive care unit (ICU) admission (e.g., postcardiac surgery), for prophylaxis/treatment of thrombosis, for hemodialysis/filtration, or even incidentally (e.g., flushing of intravascular catheters), and are therefore at risk for developing immune heparin-induced thrombocytopenia (HIT), a prothrombotic drug reaction caused by platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies. However, HIT explains at most 1 in 100 thrombocytopenic ICU patients (HIT frequency 0.3-0.5% vs. 30-50% background frequency of ICU-associated thrombocytopenia), and most patients who form anti-PF4/heparin antibodies do not develop HIT; hence, HIT overdiagnosis often occurs. This review discusses HIT-related issues relevant to ICU patients, including how to (1) distinguish HIT both clinically and serologically from non-HIT-related thrombocytopenia; (2) recognize HIT-mimicking disorders, such as the acute disseminated intravascular coagulation (DIC)/liver necrosis-limb necrosis syndrome; (3) prevent HIT in the ICU through use of low-molecular-weight heparin; and (4) treat HIT, including awareness of PTT confounding when anticoagulating patients with DIC. Copyright © 2015 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York.


Bader M.S.,Hamilton Health Sciences
Postgraduate medicine | Year: 2013

Herpes zoster (Hz), which generally presents as a localized, painful cutaneous eruption, is a common clinical problem, particularly among adults ≥ 50 years of age and immunocompromised patients. The diagnosis of Hz is mainly made clinically, except in patients with atypical manifestations or certain complications, such as central nervous system involvement, in which laboratory virologic testing is required. In addition to having a higher mortality rate, immunocompromised individuals have atypical and severe clinical findings and are at greater risk for complications and recurrence of Hz. Treatment of Hz includes the use of antiviral agents, analgesics for control of acute zoster pain, good skin care for healing, and prevention of secondary bacterial infection. Antiviral agents, preferably valacyclovir or famciclovir, should be started within 72 hours of onset to reduce the severity of the infection, the duration of the eruptive phase, and the intensity of acute pain. Herpes zoster has been associated with several complications, of which post-herpetic neuralgia (PHN) is the most common and debilitating. Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent PHN. The options for treating PHN include topical agents, such as lidocaine patches, and systemic agents, such as the anticonvulsants gabapentin and pregabalin. Measures for preventing Hz include infection control through routine hand hygiene and appropriate use of isolation precautions and personal protective equipment; immunoglobulins, such as the varicella-zoster virus immunoglobulin and vaccine; and antiviral agents. The zoster vaccine has been shown to be effective in reducing the incidence of Hz and PHN. The vaccine is recommended for all individuals aged ≥ 60 years who have no contraindications, including individuals who report a previous episode of Hz.

Loading Hamilton Health Sciences collaborators
Loading Hamilton Health Sciences collaborators